Monopar Therapeutics’ (MNPR) Hold Rating Reiterated at Jones Trading

Jones Trading restated their hold rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note released on Wednesday morning,Benzinga reports.

A number of other brokerages have also commented on MNPR. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Monopar Therapeutics in a report on Tuesday. Piper Sandler reissued an “overweight” rating and set a $76.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.

Monopar Therapeutics Stock Performance

MNPR stock opened at $38.53 on Wednesday. Monopar Therapeutics has a 1 year low of $1.72 and a 1 year high of $54.30. The stock has a market capitalization of $235.11 million, a price-to-earnings ratio of -19.56 and a beta of 1.18. The stock’s fifty day moving average is $38.61 and its two-hundred day moving average is $24.63.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($0.36) by ($1.87). As a group, analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. acquired a new position in Monopar Therapeutics during the fourth quarter valued at approximately $3,694,000. Janus Henderson Group PLC bought a new stake in shares of Monopar Therapeutics during the 4th quarter worth $23,435,000. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics in the 4th quarter valued at $45,000. Geode Capital Management LLC raised its holdings in Monopar Therapeutics by 174.4% in the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after acquiring an additional 24,530 shares during the period. Finally, RA Capital Management L.P. acquired a new position in Monopar Therapeutics during the 4th quarter worth $11,247,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.